Form 8-K HALOZYME THERAPEUTICS, For: Jan 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St set for lower open as bond yields climb; Walmart falls
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Halozyme provides preliminary 2025 revenue estimates
January 28, 2026 6:41 AM ESTHalozyme Therapeutics Inc. (NASDAQ: HALO) provided preliminary financial estimates for 2025 during a January 28 investor conference call and press release.
The company estimated 2025 revenue in the range of $1.385 billion to $1.4 billion. Royalties are projected between $865 million and $870 million, while product sales are estimated at $372 million to... More
